These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 27693556)

  • 1. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
    Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
    Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
    Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
    Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
    Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
    J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study.
    Seymour EK; Khan HY; Li Y; Chaker M; Muqbil I; Aboukameel A; Ramchandren R; Houde C; Sterbis G; Yang J; Bhutani D; Pregja S; Reichel K; Huddlestun A; Neveux C; Corona K; Landesman Y; Shah J; Kauffman M; Shacham S; Mohammad RM; Azmi AS; Zonder JA
    Clin Cancer Res; 2021 Jun; 27(12):3307-3316. PubMed ID: 33785483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
    Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
    J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.
    Garg M; Kanojia D; Mayakonda A; Said JW; Doan NB; Chien W; Ganesan TS; Chuang LS; Venkatachalam N; Baloglu E; Shacham S; Kauffman M; Koeffler HP
    Oncotarget; 2017 Jan; 8(5):7521-7532. PubMed ID: 27893412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.
    Abeykoon JP; Wu X; Nowakowski KE; Dasari S; Paludo J; Weroha SJ; Hu C; Hou X; Sarkaria JN; Mladek AC; Phillips JL; Feldman AL; Ravindran A; King RL; Boysen J; Stenson MJ; Carr RM; Manske MK; Molina JR; Kapoor P; Parikh SA; Kumar S; Robinson SI; Yu J; Boughey JC; Wang L; Goetz MP; Couch FJ; Patnaik MM; Witzig TE
    Blood; 2021 Jan; 137(4):513-523. PubMed ID: 33507295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
    Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
    Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
    [No Abstract]   [Full Text] [Related]  

  • 15. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
    BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRM1 as a new therapeutic target for non-Hodgkin lymphoma.
    Han X; Wang J; Shen Y; Zhang N; Wang S; Yao J; Shi Y
    Leuk Res; 2015 Jan; 39(1):38-46. PubMed ID: 25466285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
    Azmi AS; Muqbil I; Wu J; Aboukameel A; Senapedis W; Baloglu E; Bollig-Fischer A; Dyson G; Kauffman M; Landesman Y; Shacham S; Philip PA; Mohammad RM
    Sci Rep; 2015 Nov; 5():16077. PubMed ID: 26536918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
    Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
    Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.
    Nakayama R; Zhang YX; Czaplinski JT; Anatone AJ; Sicinska ET; Fletcher JA; Demetri GD; Wagner AJ
    Oncotarget; 2016 Mar; 7(13):16581-92. PubMed ID: 26918731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
    Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2016 Feb; 63(2):276-86. PubMed ID: 26398108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.